advertisement
Abstract #47834 Published in IGR 13-4
Ocular discomfort, compliance and intra-ocular pressure (IOP) control in patients treated for glaucoma
Lafuma A; Robert J; Berdeaux GValue in Health 2011; 14: A502
OBJECTIVES: To investigate the associations between ocular discomfort, compliance and efficacy of IOP lowering drugs. METHODS: This was a prospective observational survey. Centres were selected at random from the CEGEDIM list. Consecutive patients treated with an IOP lowering fixed combination drug (prostaglandin analogues excluded) were included. IOP was collected at two visits (delay fixed by the investigator). Self-reported compliance measured by validated questionnaires (EDSQ, TSQM and TEO) and self-reported ocular discomfort (13 items with a focus at instillation and during the day) based on a questionnaire developed according to international patient reported outcome recommendations were collected at the last visit. Patients were classified into 3 groups of compliance (good, minor and major issues) using the TEO published algorithm. Comparisons between compliance groups were made by ANOVA and chi-square tests. Adjustments were made for confounding variable unbalances. RESULTS: 410 patients (66 years old, 237 females, 101 ocular hypertensions) were included. 32.9% reported good compliance, 55.9% minor and 11.2% major compliance issues. Patients reporting either red eyes (P=0.02), stinging (P=0.007), feeling of sand in the eyes (P=0.0009), dry eye (P=0.02), or blurry vision (P=0.002) were more likely to report compliance issues. Patients in the good compliance group reported 3.2 ocular discomfort concerns, 4.5 in the minor and 5.2 in the major compliance issue group (P=0.0002). The probabilities to report no concern were 24.2%, 12.7% and 11.9% (P=0.02), respectively. An association between IOP control and compliance was reported in the group of patients that did not have a change in treatment at the first visit: patients in the good compliance group had an IOP decrease of 0.9 mmHg, 0.3 mmHg in the minor and a 0.2 mmHg increase in the major compliance issue group. CONCLUSIONS: Ocular discomfort issues reported by patients might impact compliance leading to poor IOP control.
A. Lafuma. CEMKA-EVAL, Bourg la Reine, France.
Classification:
1.4 Quality of life (Part of: 1 General aspects)
11.17 Cooperation with medical therapy e.g. persistency, compliance, adherence (Part of: 11 Medical treatment)
